1050 ET - Novo Nordisk's headline phase 1 results for amycretin are highly encouraging, Deutsche Bank analyst Emmanuel Papadakis writes. Amycretin is potentially instrumental to the investment case, and thus the results are a clear minor positive, he adds. Deutsche Bank continues to believe the disappointment over CagriSema's initial headline results is overdone, and hence the subsequent derating is a clear buying opportunity. The bank rates Novo Nordisk at buy with a 900 Danish kroner target price. Shares trade 1.8% lower following Friday's strong rally on the news. (dominic.chopping@wsj.com)
(END) Dow Jones Newswires
January 27, 2025 10:50 ET (15:50 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.